|
1
|
Gharaee-Kermani M and Phan SH: Molecular
mechanisms of and possible treatment strategies for idiopathic
pulmonary fibrosis. Curr Pharm Des. 11:3943–3971. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hagiwara S, Iwasaka H, Matsumoto S and
Noguchi T: Antisense oligonucleotide inhibition of heat shock
protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in
rats. Respir Res. 8:372007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohashi S, Abe H, Takahashi T, Yamamoto Y,
Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H and Doi
T: Advanced glycation end products increase collagen-specific
chaperone protein in mouse diabetic nephropathy. J Biol Chem.
279:19816–19823. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen L, Wang T, Wang X, Sun BB, Li JQ, Liu
DS, Zhang SF, Liu L, Xu D, Chen YJ and Wen FQ: Blockade of advanced
glycation end product formation attenuates bleomycin-induced
pulmonary fibrosis in rats. Respir Res. 10:552009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang T, Chen M and Sun T: Simvastatin
attenuates TGF-beta1-induced epithelial-mesenchymal transition in
human alveolar epithelial cells. Cell Physiol Biochem. 31:863–874.
2013. View Article : Google Scholar
|
|
6
|
Ou XM, Feng YL, Wen FQ, Huang XY, Xiao J,
Wang K and Wang T: Simvastatin attenuates bleomycin-induced
pulmonary fibrosis in mice. Chin Med J (Engl). 121:1821–1829.
2008.
|
|
7
|
Zhu T, Zhang W, Xiao M, Chen H and Jin H:
Protective role of andrographolide in bleomycin-induced pulmonary
fibrosis in mice. Int J Mol Sci. 14:23581–23596. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tzouvelekis A, Paspaliaris V, Koliakos G,
et al: A prospective, non-randomized, no placebo-controlled, phase
Ib clinical trial to study the safety of the adipose derived
stromal cells-stromal vascular fraction in idiopathic pulmonary
fibrosis. J Transl Med. 11:1712013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woodcock HV, Molyneaux PL and Maher TM:
Reducing lung function decline in patients with idiopathic
pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther.
7:503–510. 2013.PubMed/NCBI
|
|
10
|
Raghu G, Collard HR, Egan JJ, et al: An
official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:
evidence-based guidelines for diagnosis and management. Am J Respir
Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Atemnkeng MA, Chimanuka B, Dejaegher B,
Heyden YV and Plaizier-Vercammen J: Evaluation of Artemisia annua
infusion efficacy for the treatment of malaria in Plasmodium
chabaudi chabaudi infected mice. Exp Parasitol. 122:344–348. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nealon C, Dzeing A, Müller-Römer U,
Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D and Krishna S:
Intramuscular bioavailability and clinical efficacy of artesunate
in gabonese children with severe malaria. Antimicrob Agents
Chemother. 46:3933–3939. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Batty KT, Le AT, Ilett KF, Nguyen PT,
Powell SM, Nguyen CH, Truong XM, Vuong VC, Huynh VT, Tran QB,
Nguyen VM and Davis TM: A pharmacokinetic and pharmacodynamic study
of artesunate for vivax malaria. Am J Trop Med Hyg. 59:823–827.
1998.PubMed/NCBI
|
|
14
|
Li H, Gu C, Ren Y, et al: The efficacy of
NP11-4-derived immunotoxin scFv-artesunate in reducing hepatic
fibrosis induced by Schistosoma japonicum in mice. J Biomed Res.
25:148–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ashcroft T, Simpson JM and Timbrell V:
Simple method of estimating severity of pulmonary fibrosis on a
numerical scale. J Clin Pathol. 41:467–470. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Willis BC, Liebler JM, Luby-Phelps K,
Nicholson AG, Crandall ED, du Bois RM and Borok Z: Induction of
epithelial-mesenchymal transition in alveolar epithelial cells by
transforming growth factor-beta1: potential role in idiopathic
pulmonary fibrosis. Am J Pathol. 166:1321–1332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cu A, Ye Q, Sarria R, Nakamura S, Guzman J
and Costabel U: N-acetylcysteine inhibits TNF-alpha, sTNFR and
TGF-beta1 release by alveolar macrophages in idiopathic pulmonary
fibrosis in vitro. Sarcoidosis Vasc Diffuse Lung Dis. 26:147–154.
2009.
|
|
18
|
Bartram U and Speer CP: The role of
transforming growth factor beta in lung development and disease.
Chest. 125:754–765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leask A and Abraham DJ: TGF-beta signaling
and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sasaki H, Sato T, Yamauchi N, et al:
Induction of heat shock protein 47 synthesis by TGF-beta and IL-1
beta via enhancement of the heat shock element binding activity of
heat shock transcription factor 1. J Immunol. 168:5178–5183. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koide T, Asada S and Nagata K: Substrate
recognition of collagen-specific molecular chaperone HSP47.
Structural requirements and binding regulation. J Biol Chem.
274:34523–34526. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inoue K, Naito Y, Takagi T, et al:
Daikenchuto, a Kampo medicine, regulates intestinal fibrosis
associated with decreasing expression of heat shock protein 47 and
collagen content in a rat colitis model. Biol Pharm Bull.
34:1659–1665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kakugawa T, Mukae H, Hishikawa Y, Ishii H,
Sakamoto N, Ishimatsu Y, Fujii T, Koji T and Kohno S: Localization
of HSP47 mRNA in murine bleomycin-induced pulmonary fibrosis.
Virchows Arch. 456:309–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
